The efficacy and safety of switching from linagliptin to once-weekly dulaglutide in hemodialysis patients with type 2 diabetes mellitus (pilot study)

The efficacy and safety of switching from linagliptin to once-weekly dulaglutide in hemodialysis patients with type 2 diabetes mellitus (pilot study) - The efficacy of linagliptin and dulaglutide in hemodialysis patients with type 2 diabetes mellitus

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021944

Enrollment

Registered

2016-04-26

Start date

2016-04-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

The target patients switch from linagliptin to once-weekly 0.75mg dulaglutide. We follow it up for 26 weeks. In the patient using insulin with hypoglycemic risk, insulin dose was adjusted once or twic

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Type 2 diabetes patients who passed more than three months after the dialysis introduction. 2)The patients with linagliptin who satisfy more than 7.0% HbA1c or more than 20.0% glycoalbumin. 3)BMI is more than 22.0kg/m2

Exclusion criteria

Exclusion criteria: 1)Patients with severe gastroparesis 2)The patient with the medical history of the pancreatitis 3)Patients who have a medical history of hypersensitivity 4)Pregnant or possibly pregnant women and women on lactation 5)Ineligible patients according to the investigator&#39;s judgment 6)The patients who do not agree with this study

Design outcomes

Primary

Measure	Time frame
The amount changes of glycoalbuin and hemoglobin A1c for 26 weeks The amount changes of daily use insulin in the patients who treated with insulin for 26 weeks	—

Secondary

Measure	Time frame
The amount changes of glycoalbuin and hemoglobin A1c for 12 weeks The amount changes of average body weight before dialysis for one week, self monitoring blood glucose, plasma glucose before hemodialysis, UA, TG, HDL-Cho, LDL-Cho, C-peptide, adverse events	—

Countries

Japan

Contacts

Public ContactTetsuri Yamashita

Tokyo Women`s Medical University Medical Center East Internal Medicine

tetsuri218@yahoo.co.jp03-3810-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026